The University of Tokushima is a national university in the city of Tokushima, Japan, with seven graduate schools and five undergraduate faculties. The university was founded in 1949, by merging six national education facilities into one. The 2014 Nobel Prize Laureate in Physics, Shuji Nakamura graduated from Tokushima. Wikipedia.
News Article | May 22, 2017
Another intriguing virtual take-off and landing (VTOL) vehicle is receiving high-profile attention, this time from Toyota, which is investing into the SkyDrive Cartivator VTOL. Although Toyota has been resting on the success of its Prius for some time now, it decided to surprise us with not another hybrid or the fully electric vehicles (EV) everyone seems to ask Toyota to build, but it won’t. Instead, Toyota decided to invest into a Japanese flying car research project — the SkyDrive Cartivator VTOL. What the project aims to do is simple — show that flying cars are a reality and are aiming for the Tokyo 2020 Olympics, where it hopes to light the Olympic Flame. Toyota invested no less than 42.5 million yen (a little over $380,000) in this. And the Cartivator project has a few interesting angles. This three-wheeled light VTOL, dubbed the SkyDrive, will show that flying cars can take off from anywhere and don’t have to be big either. The SkyDrive Cartivator VTOL will use a four-propeller set design to get a 2.9 meter by 1.3 meter (9.5 foot by 4.5 foot) VTOL in the air. This will be the world’s smallest flying car. And there is much to say about this, since space and availability, as well as affordability, is what many traffic-jammed commuters are asking for. The SkyDrive Cartivator VTOL will have a top flight speed of 100 km/h (62 miles) at 10 meters (33 feet) high. But don’t despair, its land top speed will be much higher at 150 km/h (roughly 93 mph). VTOLs are everywhere this year and availability and ease of use is what we’re looking for. So how is the SkyDrive Cartivator VTOL innovating in that aspect? According to the Cartivator team, the SkyDrive Cartivator VTOL able to take off from public roads and able to be controlled by intuitive operation. We love that first part. However, we will wait until we see what is meant by “intuitive operations.” If the SkyDrive Cartivator VTOL is to come pick you up after you hail and go somewhere with very limited user input, that should be fairly easy. Most of those things can be done from a smartphone these days. However, anything more complicated will require much more forethought. The SkyDrive Cartivator VTOL project started in 2012 when Representative Nakamura and his friends won the first prize at business contest “KOREARATA.” They named their team “CARTIVATOR.” After that, two years later, they started development of flying car “SkyDrive.” Seven months in, they had a 1/5 scale flying model. Another six months and they joined development with Mr.Hirano, associated with the Flying Chair project with Associate Prof. Miwa from Tokushima University. In 2015, they won the prize at “IVS Launch Pad 2016 Spring.” And this is where they are now, with Toyota investing in them, amongst a few other players. So far, we’ve seen flying taxi cars, driving helicopters and airplanes, and heck, even flying saucer-like VTOLs and bike-like VTOLs. What the SkyDrive Cartivator VTOL suggests, though, is something simple, something primal that should appease almost everyone’s needs. A small flying commuter, away from flying fortresses and other heavier projects. So, could this be the flying Prius? Check out our new 93-page EV report. Join us for an upcoming Cleantech Revolution Tour conference! Keep up to date with all the hottest cleantech news by subscribing to our (free) cleantech daily newsletter or weekly newsletter, or keep an eye on sector-specific news by getting our (also free) solar energy newsletter, electric vehicle newsletter, or wind energy newsletter.
Tokushima University and Fujikin Incorporated | Date: 2015-07-23
An inline concentration measurement device comprises: a measurement cell main body with a gas flow path formed; a light incident part with a window member connected to the main body; and a light receiving part with a window member connected to the main body, wherein the gas flow path includes a gas flow path for an optical path extending straight between the window members of the light incident part and the light receiving part, a first communication part making a gas inlet formed in the main body communicate with the gas flow path part for the optical path, and a second communication part making a gas outlet formed in the main body communicate with the gas flow path part for the optical path, and the first communication part obliquely extends from the gas inlet towards the window member of the light incident part.
Kashihara K.,Tokushima University
Frontiers in Neuroscience | Year: 2014
Unlike assistive technology for verbal communication, the brain-machine or brain-computer interface (BMI/BCI) has not been established as a nonverbal communication tool for amyotrophic lateral sclerosis (ALS) patients. Face-to-face communication enables access to rich emotional information, but individuals suffering from neurological disorders, such as ALS and autism, may not express their emotions or communicate their negative feelings. Although emotions may be inferred by looking at facial expressions, emotional prediction for neutral faces necessitates advanced judgment. The process that underlies brain neuronal responses to neutral faces and causes emotional changes remains unknown. To address this problem, therefore, this study attempted to decode conditioned emotional reactions to neutral face stimuli. This direction was motivated by the assumption that if electroencephalogram (EEG) signals can be used to detect patients' emotional responses to specific inexpressive faces, the results could be incorporated into the design and development of BMI/BCI-based nonverbal communication tools. To these ends, this study investigated how a neutral face associated with a negative emotion modulates rapid central responses in face processing and then identified cortical activities. The conditioned neutral face-triggered event related potentials that originated from the posterior temporal lobe statistically significantly changed during late face processing (600-700 ms) after stimulus, rather than in early face processing activities, such as P1 and N170 responses. Source localization revealed that the conditioned neutral faces increased activity in the right fusiform gyrus. This study also developed an efficient method for detecting implicit negative emotional responses to specific faces by using EEG signals. A classification method based on a support vector machine enables the easy classification of neutral faces that trigger specific individual emotions. In accordance with this classification, a face on a computer morphs into a sad or displeased countenance. The proposed method could be incorporated as a part of nonverbal communication tools to enable emotional expression.
Kaji R.,Tokushima University
Toxicon | Year: 2015
All the type A botulinum toxins that have been clinically used are of subtype A1. We have developed low-molecular weight (150 k Dal) subtype A2 preparation (A2NTX) for clinical use. In the first-in-man study, the clinical efficacy of A2NTX was 1.5 times that of onabotulinumtoxinA (subtype A1) with similar time course and less spread of its action to a neighboring muscle. We have recently performed a comparative study of A1LL (onabotulinumtoxinA) and A2NTX toxins for post-stroke spasticity (Study of a New Generation Botulinum Toxin A2NTX to Treat Spasticity After Stroke; NCT01910363 at ClinicalTrials.gov). This double blinded randomized controlled study used 300u of each subtype. In this study, A2NTX showed significantly higher efficacy 30 days after injection (Fig. 2), and less spread of the effect as measured by the hand grip of the unaffected side than A1LL. Functional independence measure (FIM) was also significantly improved for A2NTX, but not for A1LL. Additional large-scale clinical trials are warranted to further evaluate this promising new treatment. © 2015 Elsevier Ltd. All rights reserved.
Anderson G.,University of Birmingham |
Takahama Y.,Tokushima University
Trends in Immunology | Year: 2012
The thymus represents an epithelial-mesenchymal tissue, anatomically structured into discrete cortical and medullary regions that contain phenotypically and functionally distinct stromal cells, as well as thymocytes at defined stages of maturation. The stepwise progression of thymocyte development seems to require serial migration through these distinct thymic regions, where interactions with cortical thymic epithelial cell (cTEC) and medullary thymic epithelial cell (mTEC) subsets take place. Recent work on TEC subsets provides insight into T cell development and selection, such as the importance of tumour necrosis factor (TNF) receptor superfamily members in thymus medulla development, and the specialised antigen processing/presentation capacity of the thymic cortex for positive selection. Here, we summarise current knowledge on the development and function of the thymic microenvironment, paying particular attention to the cortical and medullary epithelial compartments. © 2012 Elsevier Ltd.
SBI Pharmaceuticals Co. and Tokushima University | Date: 2015-05-27
Provided is a prophylactic/therapeutic agent for influenza viral infection that is effective not only before and at an early stage of infection with influenza virus but also at an intermediate or late stage of the infection and is highly safe for human bodies. A prophylactic/therapeutic drug for influenza viral infection comprising, as active ingredients, 5-aminolevulinic acid (5-ALA), a derivative thereof or a salt of the 5-ALA or the derivative, and an iron compound is prepared. This prophylactic/therapeutic agent can be used for ameliorating (preventing) depression in food consumption, water consumption and body weight, for ameliorating (decreasing) increase in ketone body levels in blood that may otherwise cause ketosis, for ameliorating (preventing) depression in ATP levels in blood, or for ameliorating (increasing) a survival rate and depression in a body surface temperature.
Tokushima University and Lsip Llc | Date: 2015-08-19
Provided is a radiation intensity measuring apparatus for each of small sealed radiation sources for cancer therapy capable of measuring multiple cartridges efficiently and rapidly. A radiation intensity measuring apparatus for radiation sources S in the state that the multiple radiation sources S are packed in a seed cartridge SC of a cartridge C, includes holding means 10 capable of holding the multiple cartridges C; radiation intensity measuring means 30 for measuring intensity of the radiation emitted from the multiple radiation sources S; and moving means 20 for moving the radiation intensity measuring means 30 toward or away from the holding means 10, and the radiation intensity measuring means 30 includes: a sensor 31 for measuring radiation intensity, and a shielding member 35 having a slit 35h provided for restricting radiation irradiated to the sensor 31; and the moving means 20 is configured to be able to relatively move the radiation intensity measuring means 30 along the direction in which the multiple radiation sources S are arranged in the measurement state.
Tokushima University, Meiji Pharmaceutical University and Lsip Llc | Date: 2015-08-26
Provided is a modified -subunit of human -hexosaminidase which has the activity derived from the -subunit of wild-type human -hexosaminidase and has the resistance to protease. A protein comprising an amino acid sequence having substitutions of the 312th to the 318th amino acids with glycine, serine, glutamic acid, proline, serine, glycine and threonine in order, respectively, in an amino acid sequence of a -subunit of wild-type human -hexosaminidase.
Tokushima University and Saisei Mirai Clinic | Date: 2015-01-21
An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with -galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method.
Tokushima University | Date: 2015-08-19
An object of the present invention is to provide a method for quickly acquiring three-dimensional shape data of upper and lower tooth rows. The present invention provides a method for calculating a distance between the upper and lower tooth rows at a high speed, from the three-dimensional shape data of the upper and lower tooth rows thus acquired. Based on technology behind the above methods, the present invention provides a method and an apparatus for performing simulation display of the three-dimensional shapes and an occlusal contact region of the upper and lower tooth rows at a high speed. A jaw movement sensor 30 is fitted to an examinee, and jaw movement data 35 on jaw movement of the examinee is acquired. An impression plate 20 including a rigid flat plate having a top surface and a bottom surface each coated with an impression material is inserted between upper and lower tooth rows of the examinee to which the jaw movement sensor 30 is fitted, and the examinee is guided to perform a temporary occlusion. Impressions left on the impression material 20 and a gauge mark provided on the rigid flat plate are measured by using a three-dimensional shape measuring instrument 25, whereby the three-dimensional shape data of the upper and lower tooth rows and gauge mark data are acquired. Simulation display of movement of the upper and lower tooth rows and occlusal contact regions of the examinee is performed based on the three-dimensional shape data of the upper and lower tooth rows and the gauge mark data, and jaw position data at a time of temporary occlusion and the jaw movement data.